HRP20211493T1 - Receptori t stanica - Google Patents
Receptori t stanica Download PDFInfo
- Publication number
- HRP20211493T1 HRP20211493T1 HRP20211493TT HRP20211493T HRP20211493T1 HR P20211493 T1 HRP20211493 T1 HR P20211493T1 HR P20211493T T HRP20211493T T HR P20211493TT HR P20211493 T HRP20211493 T HR P20211493T HR P20211493 T1 HRP20211493 T1 HR P20211493T1
- Authority
- HR
- Croatia
- Prior art keywords
- amino acid
- sequence
- acid residues
- seq
- tcr
- Prior art date
Links
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 title claims 28
- 108091008874 T cell receptors Proteins 0.000 title claims 27
- 125000000539 amino acid group Chemical group 0.000 claims 37
- 125000003275 alpha amino acid group Chemical group 0.000 claims 8
- 150000007523 nucleic acids Chemical class 0.000 claims 7
- 102000039446 nucleic acids Human genes 0.000 claims 7
- 108020004707 nucleic acids Proteins 0.000 claims 7
- 102100024092 Aldo-keto reductase family 1 member C4 Human genes 0.000 claims 4
- 101710117290 Aldo-keto reductase family 1 member C4 Proteins 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 4
- 239000013604 expression vector Substances 0.000 claims 3
- 108010012015 GVYDGREHTV Proteins 0.000 claims 2
- 108010088729 HLA-A*02:01 antigen Proteins 0.000 claims 2
- 108700026244 Open Reading Frames Proteins 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000035772 mutation Effects 0.000 claims 2
- 108010075704 HLA-A Antigens Proteins 0.000 claims 1
- 102000011786 HLA-A Antigens Human genes 0.000 claims 1
- 101000795989 Homo sapiens T cell receptor alpha variable 10 Proteins 0.000 claims 1
- 101000939745 Homo sapiens T cell receptor beta variable 24-1 Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 102100031333 T cell receptor alpha variable 10 Human genes 0.000 claims 1
- 102100029656 T cell receptor beta variable 24-1 Human genes 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000037430 deletion Effects 0.000 claims 1
- 238000012217 deletion Methods 0.000 claims 1
- 238000010494 dissociation reaction Methods 0.000 claims 1
- 230000005593 dissociations Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000833 heterodimer Substances 0.000 claims 1
- 238000003780 insertion Methods 0.000 claims 1
- 230000037431 insertion Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464484—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/464486—MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
Claims (17)
1. T stanični receptor (TCR) koji ima svojstvo vezanja za GVYDGREHTV (SEQ ID No: 1) u kompleksu s HLA-A*0201 s konstantom disocijacije od oko 0.05 µM do oko 20.0 µM ako se mjeri površinskom plazmonskom rezonancijom na 25°C i pri pH između 7.1 i 7.5 koristeći topljivi oblik TCR-a i ima najmanje deseterostruku selektivnost vezanja na SEQ ID No: 1 u kompleksu s HLA-A*0201 preko vezanja na GVYDGEEHSV (SEQ ID No 2) u kompleksu s HLA-A*0201 gdje TCR sadrži varijabilnu domenu TCR alfa lanca i varijabilnu domenu TCR beta lanca, i gdje varijabilne domene TCR tvore kontakte s najmanje ostacima V2, Y3 i D4 GVYDGREHTV (SEQ ID No: 1).
2. TCR prema zahtjevu 1, koji je alfa-beta heterodimer, koji ima alfa lanac TRAV10 + TRAC sekvencu konstantne domene i beta lanac TRBV24-1 + TRBC-2 sekvencu konstantne domene.
3. TCR prema zahtjevu 1, koji je u jednolančanom formatu tipa Vα-L-Vβ, Vβ-L-Vα, Vα-Cα-L-Vβ ili Vα-L-Vβ-Cβ, gdje Vα i Vβ su TCR α i β varijabilna područja, Cα i Cβ su TCR α i β konstantna područja respektivno, i L je vezna sekvenca.
4. TCR prema bilo kojem prethodnom zahtjevu, koji je povezan s detektibilnom oznakom, terapijskim sredstvom ili dijelom koji modificira PK.
5. TCR prema bilo kojem od prethodnih zahtjeva, naznačen time što varijabilna domena alfa lanca sadrži aminokiselinsku sekvencu koja ima najmanje 80% identičnosti sa sekvencom aminokiselinskih ostataka 1-105 SEQ ID No: 3 i ima sljedeću CDR mutaciju:
M4 V ili L
s pozivom na numeriranje CDR-a prikazanih u SEQ ID No: 3, i/ili varijabilna domena beta lanca sadrži aminokiselinsku sekvencu koja ima najmanje 80% identičnosti sa sekvencom aminokiselinskih ostataka 1-105 SEQ ID No: 4 i ima barem jednu od sljedećih CDR mutacija:
[image]
s pozivom na numeriranje CDR -ova prikazanih u SEQ ID No: 4.
6. TCR prema bilo kojem od prethodnih zahtjeva, naznačen time što je varijabilna domena alfa lanca sekvenca varijabilne domene alfa lanca navedena u SEQ ID No. 3 i varijabilna domena beta lanca je sekvenca varijabilne domene beta lanca navedena u SEQ ID No. 9; ili je varijabilna domena alfa lanca sekvenca varijabilne domene alfa lanca navedena u SEQ ID No. 7 i varijabilna domena beta lanca je sekvenca varijabilne domene beta lanca navedena u SEQ ID No. 9; ili je varijabilna domena alfa lanca sekvenca varijabilne domene alfa lanca navedena u SEQ ID No. 8, i varijabilna domena beta lanca je sekvenca varijabilne domene beta lanca navedena u SEQ ID No. 9.
7. TCR prema bilo kojem od prethodnih zahtjeva, naznačen time što varijabilna domena alfa lanca sadrži aminokiselinsku sekvencu aminokiselinskih ostataka 1-105 SEQ ID No: 3 ili 5 ili 7 do 8 ili
aminokiselinsku sekvencu u kojoj aminokiselinski ostaci 1-27, 34-47, i 54-90 od njih imaju najmanje 90% ili 95% identičnosti sa sekvencom aminokiselinskih ostataka 1-27, 34-47, i 54-90 respektivno SEQ ID No: 3 ili 5 ili 7 do 8 i u kojima aminokiselinski ostaci 28-34, 48-53 i 91-105 imaju najmanje 90% ili 95% identiteta sa sekvencom aminokiselinskih ostataka 28-33, 48-53 i 91-105 respektivno SEQ ID No 3 ili 5 ili 7 do 8.
8. TCR prema bilo kojem od zahtjeva 1-7, naznačen time što varijabilna domena alfa lanca sadrži aminokiselinsku sekvencu aminokiselinskih ostataka 1-105 SEQ ID No: 7 ili 8 ili aminokiselinsku sekvencu u kojoj aminokiselinski ostaci 1 -27, 34-47 i 55-89 od njih imaju najmanje 90% ili 95% identičnosti sa sekvencom aminokiselinskih ostataka 1-27, 34-47 i 55-89 respektivno SEQ ID No: 7 ili 8 i u kojima aminokiselinski ostaci 28-33, 48-53 i 91-105 imaju najmanje 90% ili 95% identičnosti sa sekvencom aminokiselinskih ostataka 28-33, 48-53 i 91-105 respektivno SEQ ID No: 7 ili 8.
9. TCR prema bilo kojem od prethodnih zahtjeva, naznačen time što u varijabilnoj domeni alfa lanca sekvenca od
(i) njihovih aminokiselinskih ostataka 1-27 ima (a) najmanje 90% identičnosti sa sekvencom aminokiselinskih ostataka 1-26 SEQ ID No. 3 ili (b) ima jedan, dva ili tri aminokiselinska ostatka umetnutih ili obrisanih u odnosu na sekvencu (a);
(ii) aminokiselinskih ostataka 28-33 je VSPFSN;
(iii) njihovih aminokiselinskih ostataka 34-47 ima (a) najmanje 90% identičnosti sa sekvencom aminokiselinskih ostataka 34-47 SEQ ID NO: 3 ili (b) ima jedan, dva ili tri aminokiselinska ostatka umetnutih ili obrisanih u odnosu na sekvencu (a);
(iv) aminokiselinskih ostataka 48-53 je LTIMTF ili LTRMTF ili LTIVTF ili LTILTF
(v) njihovih aminokiselinskih ostataka 54-90 ima najmanje 90% identičnosti sa sekvencom aminokiselinskih ostataka 55-89 SEQ ID No: 3 ili ima jedno, dva ili tri umetanja, brisanja ili supstitucije u odnosu na njih; i
(vi) aminokiselina 91-105 je CWSGGTDSWGKLQF
10. TCR prema bilo kojem od prethodnih zahtjeva, naznačen time što varijabilna domena beta lanca sadrži aminokiselinsku sekvencu SEQ ID No: 4 ili 6 ili 9 ili aminokiselinsku sekvencu u kojoj njihovi aminokiselinski ostaci 1-45, 51-67, i 74-109 imaju najmanje 90% ili 95% identičnosti sa sekvencom aminokiselinskih ostataka 1-45, 51-67, i 74-109 respektivno SEQ ID No: 4 ili 6 ili 9 i u kojima aminokiselinski ostaci 46-50, 68-73 i 109-123 imaju najmanje 90% ili 95% identičnosti sa sekvencom aminokiselinskih ostataka 46-50, 68-73 i 109-123, respektivno SEQ ID No: 4 ili 6 ili 9.
11. TCR prema bilo kojem od prethodnih zahtjeva, naznačen time što u varijabilnoj domeni beta lanca sekvenca od
(i) njihovih aminokiselinskih ostataka 1-45 ima (a) najmanje 90% identičnosti sa sekvencom aminokiselinskih ostataka 1-26 SEQ ID No: 4 ili (b) ima jedan, dva ili tri aminokiselinska ostatka umetnutih ili obrisanih u odnosu na sekvencu (a);
(ii) aminokiselinskih ostataka 46-50 je KGHDR;
(iii) njihovih aminokiselinskih ostataka 51-67 ima (a) najmanje 90% identičnosti sa sekvencom aminokiselinskih ostataka 51-67 SEQ ID NO: 4 ili (b) ima jedan, dva ili tri aminokiselinska ostatka umetnutih ili obrisanih u odnosu na sekvencu (a);
(iv) aminokiselinskih ostataka 68-73 je SFDVK;
(v) njihovih aminokiselinskih ostataka 54-90 ima (a) najmanje 90% identičnosti sa sekvencom aminokiselinskih ostataka 54-90 SEQ ID NO: 4 ili (b) ima jedan, dva ili tri aminokiselinska ostatka umetnutih ili obrisanih u odnosu na sekvencu (a); i
(vi) aminokiselina 109-123 je CATSGQGAYNEQFF ili CATSGQGAYREQFF
12. Nukleinska kiselina koja kodira TCR prema bilo kojem od prethodnih zahtjeva.
13. Izolirana ili ne-prirodno prisutna stanica, posebno T-stanica, koja predstavlja TCR prema bilo kojem od zahtjeva 1 do 12.
14. Stanica u kojoj su smješteni
(a) ekspresijski vektor TCR-a koji sadrži nukleinsku kiselinu prema zahtjevu 13 u jednom otvorenom okviru za čitanje, ili dva različita otvorena okvira za čitanje koji kodiraju alfa i beta lanac; ili
(b) prvi ekspresijski vektor koji sadrži nukleinsku kiselinu koja kodira alfa lanac TCR-a prema bilo kojem od zahtjeva 1 do 12, i drugi ekspresijski vektor koji sadrži nukleinsku kiselinu koja kodira beta lanac TCR-a prema bilo kojem od zahtjeva 1 do 12.
15. Farmaceutski pripravak koji sadrži TCR prema bilo kojem od zahtjeva 1 do 11, nukleinsku kiselinu prema zahtjevu 12 ili stanicu prema zahtjevu 13 ili 14, zajedno s jednim ili više farmaceutski prihvatljivih nosača ili pomoćnih tvari.
16. TCR prema bilo kojem od zahtjeva 1 do 13, nukleinska kiselina prema zahtjevu 14 ili stanica prema zahtjevu 15 ili zahtjevu 16 za uporabu u medicini.
17. TCR, nukleinska kiselina ili stanica za uporabu prema zahtjevu 16, za uporabu u postupku liječenja raka.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201606177 | 2016-04-08 | ||
| PCT/EP2017/058580 WO2017174824A1 (en) | 2016-04-08 | 2017-04-10 | T cell receptors |
| EP17723016.6A EP3440106B1 (en) | 2016-04-08 | 2017-04-10 | T cell receptors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20211493T1 true HRP20211493T1 (hr) | 2022-01-21 |
Family
ID=58701592
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20211493TT HRP20211493T1 (hr) | 2016-04-08 | 2017-04-10 | Receptori t stanica |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US11286289B2 (hr) |
| EP (2) | EP3988565A1 (hr) |
| JP (2) | JP7240176B2 (hr) |
| KR (2) | KR20230044016A (hr) |
| CN (2) | CN109476725B (hr) |
| AU (2) | AU2017248122B2 (hr) |
| BR (1) | BR112018070625A2 (hr) |
| CA (1) | CA3020058A1 (hr) |
| CY (1) | CY1124664T1 (hr) |
| DK (1) | DK3440106T3 (hr) |
| ES (1) | ES2891321T3 (hr) |
| HR (1) | HRP20211493T1 (hr) |
| HU (1) | HUE056433T2 (hr) |
| IL (1) | IL262128A (hr) |
| LT (1) | LT3440106T (hr) |
| MX (2) | MX2018012269A (hr) |
| PL (1) | PL3440106T3 (hr) |
| PT (1) | PT3440106T (hr) |
| RS (1) | RS62623B1 (hr) |
| RU (1) | RU2018138838A (hr) |
| SG (1) | SG11201808751SA (hr) |
| SI (1) | SI3440106T1 (hr) |
| WO (1) | WO2017174824A1 (hr) |
| ZA (1) | ZA201806866B (hr) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201501017D0 (en) | 2014-12-23 | 2015-03-04 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers |
| PT3626729T (pt) | 2014-12-23 | 2021-11-03 | Immatics Biotechnologies Gmbh | Novos péptidos e combinações de péptidos para uso na imunoterapia contra o carcinoma hepatocelular (chc) e outros cancros |
| CN109476724B (zh) | 2016-04-08 | 2023-04-04 | 艾达普特免疫有限公司 | T细胞受体 |
| RU2018138836A (ru) * | 2016-04-08 | 2020-05-12 | Адаптимьюн Лимитед | Т-клеточные рецепторы |
| LT3440106T (lt) | 2016-04-08 | 2021-12-10 | Adaptimmune Limited | T ląstelių receptoriai |
| EP3692058A1 (en) | 2017-10-06 | 2020-08-12 | Oslo Universitetssykehus HF | Chimeric antigen receptors |
| CN109777778B (zh) * | 2017-11-14 | 2023-07-18 | 中国科学院广州生物医药与健康研究院 | 一种基因改造的γδT细胞 |
| GB201803750D0 (en) | 2018-03-08 | 2018-04-25 | Immunocore Ltd | Method |
| EP3714941A1 (en) * | 2019-03-27 | 2020-09-30 | Medigene Immunotherapies GmbH | Mage-a4 tcrs |
| BR112021025548A2 (pt) * | 2019-06-18 | 2022-05-17 | Regeneron Pharma | Receptores de células t mage-a4 e métodos de uso dos mesmos |
| MX2021015452A (es) | 2019-06-25 | 2022-02-11 | Gilead Sciences Inc | Proteinas de fusion flt3l-fc y metodos de uso. |
| EP4013857A1 (en) | 2019-08-13 | 2022-06-22 | King's College London | Immunoresponsive cells armoured with spatiotemporally restricted activity of cytokines of the il-1 superfamily |
| CN114828965A (zh) | 2019-12-18 | 2022-07-29 | 豪夫迈·罗氏有限公司 | 与hla-a2/mage-a4结合的抗体 |
| WO2021163064A2 (en) | 2020-02-14 | 2021-08-19 | Jounce Therapeutics, Inc. | Antibodies and fusion proteins that bind to ccr8 and uses thereof |
| TWI815194B (zh) | 2020-10-22 | 2023-09-11 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
| KR20230169944A (ko) | 2021-03-09 | 2023-12-18 | 씨디알-라이프 아게 | Mage-a4 펩티드-mhc 항원 결합 단백질 |
| US20220389394A1 (en) | 2021-05-18 | 2022-12-08 | Gilead Sciences, Inc. | METHODS OF USING FLT3L-Fc FUSION PROTEINS |
| EP4091627A1 (en) | 2021-05-21 | 2022-11-23 | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft | Tcr constructs specific for magea4-derived epitopes |
| CA3236237A1 (en) * | 2021-10-25 | 2023-05-04 | Board Of Regents, The University Of Texas System | Peptides and engineered t cell receptors targeting mage-a4 antigen and methods of use |
| AU2022375782A1 (en) | 2021-10-28 | 2024-05-02 | Gilead Sciences, Inc. | Pyridizin-3(2h)-one derivatives |
| AU2022376954A1 (en) | 2021-10-29 | 2024-05-02 | Gilead Sciences, Inc. | Cd73 compounds |
| WO2023122581A2 (en) | 2021-12-22 | 2023-06-29 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| AU2022417491A1 (en) | 2021-12-22 | 2024-05-23 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Ｐａｒｐ７抑制劑 |
| WO2023178181A1 (en) | 2022-03-17 | 2023-09-21 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| GB202205572D0 (en) | 2022-04-14 | 2022-06-01 | Adaptimmune Ltd | Engineered T cells |
| TW202400138A (zh) | 2022-04-21 | 2024-01-01 | 美商基利科學股份有限公司 | Ｋｒａｓ ｇ１２ｄ調節化合物 |
| WO2024006929A1 (en) | 2022-07-01 | 2024-01-04 | Gilead Sciences, Inc. | Cd73 compounds |
| AU2023241306A1 (en) * | 2022-10-05 | 2024-05-02 | Tscan Therapeutics, Inc. | Prame immunogenic peptides, binding proteins recognizing prame immunogenic peptides, and uses thereof |
| AU2023241307A1 (en) * | 2022-10-05 | 2024-05-02 | Tscan Therapeutics, Inc. | Magea1 immunogenic peptides, binding proteins recognizing magea1 immunogenic peptides, and uses thereof |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0869943A1 (en) * | 1995-12-08 | 1998-10-14 | Smithkline Beecham Plc | Monocyclic beta-lactame derivatives for treatment of atherosclerosis |
| AU5992999A (en) | 1998-10-02 | 2000-04-26 | Ludwig Institute For Cancer Research | Tumor antigens and ctl clones isolated by a novel procedure |
| US7157091B1 (en) | 1999-06-18 | 2007-01-02 | Ludwig Institute For Cancer Research | MAGE-A1 peptides presented by HLA class II molecules |
| US6867283B2 (en) | 2001-05-16 | 2005-03-15 | Technion Research & Development Foundation Ltd. | Peptides capable of binding to MHC molecules, cells presenting such peptides, and pharmaceutical compositions comprising such peptides and/or cells |
| US7049413B2 (en) | 2001-05-18 | 2006-05-23 | Ludwig Institute For Cancer Research | MAGE-A3 peptides presented by HLA class II molecules |
| PL208712B1 (pl) | 2001-08-31 | 2011-05-31 | Avidex Ltd | Rozpuszczalny receptor komórek T (sTCR), rozpuszczalna αβ-postać receptora komórek T (sTCR), wielowartościowy kompleks receptora komórek T (TCR), sposób wykrywania kompleksów MHC-peptyd, środek farmaceutyczny zawierający sTCR i/lub wielowartościowy kompleks TCR, cząsteczka kwasu nukleinowego, wektor, komórka gospodarz, sposób otrzymywania całości lub części łańcucha α TCR albo całości lub części łańcucha β TCR, sposób otrzymywania rozpuszczalnego receptora komórek T (sTCR), sposób otrzymywania rozpuszczalnej αβ-postaci receptora komórek T (sTCR) oraz sposób wykrywania kompleksów MHC-peptyd |
| RU2355703C2 (ru) | 2002-10-09 | 2009-05-20 | Медиджен Лимитед | Одноцепочечные рекомбинантные т-клеточные рецепторы |
| GB0304068D0 (en) * | 2003-02-22 | 2003-03-26 | Avidex Ltd | Substances |
| KR101130597B1 (ko) | 2005-09-13 | 2012-04-02 | 다카라 바이오 가부시키가이샤 | Ｔ 세포 리셉터 및 그 리셉터를 코드하는 핵산 |
| LT2618835T (lt) * | 2010-09-20 | 2017-10-10 | Biontech Cell & Gene Therapies Gmbh | Antigenui specifiniai t ląstelių receptoriai ir t ląstelių epitopai |
| EA201400447A1 (ru) * | 2011-10-14 | 2014-09-30 | Тева Фармасьютикал Австралия Пти Лтд. | АНТИТЕЛА К CD1d |
| CN109476724B (zh) | 2016-04-08 | 2023-04-04 | 艾达普特免疫有限公司 | T细胞受体 |
| LT3440106T (lt) | 2016-04-08 | 2021-12-10 | Adaptimmune Limited | T ląstelių receptoriai |
| RU2018138836A (ru) | 2016-04-08 | 2020-05-12 | Адаптимьюн Лимитед | Т-клеточные рецепторы |
-
2017
- 2017-04-10 LT LTEPPCT/EP2017/058580T patent/LT3440106T/lt unknown
- 2017-04-10 HU HUE17723016A patent/HUE056433T2/hu unknown
- 2017-04-10 CA CA3020058A patent/CA3020058A1/en active Pending
- 2017-04-10 DK DK17723016.6T patent/DK3440106T3/da active
- 2017-04-10 MX MX2018012269A patent/MX2018012269A/es unknown
- 2017-04-10 WO PCT/EP2017/058580 patent/WO2017174824A1/en active Application Filing
- 2017-04-10 EP EP21193647.1A patent/EP3988565A1/en active Pending
- 2017-04-10 ES ES17723016T patent/ES2891321T3/es active Active
- 2017-04-10 KR KR1020237007661A patent/KR20230044016A/ko not_active Application Discontinuation
- 2017-04-10 CN CN201780031710.2A patent/CN109476725B/zh active Active
- 2017-04-10 PT PT177230166T patent/PT3440106T/pt unknown
- 2017-04-10 BR BR112018070625A patent/BR112018070625A2/pt unknown
- 2017-04-10 JP JP2018552872A patent/JP7240176B2/ja active Active
- 2017-04-10 RU RU2018138838A patent/RU2018138838A/ru unknown
- 2017-04-10 SI SI201730915T patent/SI3440106T1/sl unknown
- 2017-04-10 EP EP17723016.6A patent/EP3440106B1/en active Active
- 2017-04-10 CN CN202310190624.3A patent/CN116217703A/zh active Pending
- 2017-04-10 AU AU2017248122A patent/AU2017248122B2/en active Active
- 2017-04-10 PL PL17723016T patent/PL3440106T3/pl unknown
- 2017-04-10 SG SG11201808751SA patent/SG11201808751SA/en unknown
- 2017-04-10 KR KR1020187032168A patent/KR102523449B1/ko active IP Right Grant
- 2017-04-10 RS RS20211132A patent/RS62623B1/sr unknown
- 2017-04-10 HR HRP20211493TT patent/HRP20211493T1/hr unknown
-
2018
- 2018-10-04 IL IL262128A patent/IL262128A/en unknown
- 2018-10-05 MX MX2022011309A patent/MX2022011309A/es unknown
- 2018-10-08 US US16/154,192 patent/US11286289B2/en active Active
- 2018-10-15 ZA ZA2018/06866A patent/ZA201806866B/en unknown
-
2021
- 2021-10-05 CY CY20211100860T patent/CY1124664T1/el unknown
- 2021-10-14 US US17/501,122 patent/US11725040B2/en active Active
-
2022
- 2022-08-17 US US17/820,529 patent/US11572400B1/en active Active
- 2022-10-20 AU AU2022256177A patent/AU2022256177A1/en active Pending
-
2023
- 2023-03-03 JP JP2023032695A patent/JP2023081949A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20211493T1 (hr) | Receptori t stanica | |
| RU2018138836A (ru) | Т-клеточные рецепторы | |
| WO2017174823A4 (en) | T cell receptors | |
| HRP20201156T1 (hr) | Zajednički laki lanci i postupci primjene | |
| CN108883164B (zh) | 针对tigit的抗体 | |
| RU2762255C2 (ru) | Т-клеточные рецепторы | |
| RU2018142573A (ru) | Партнеры по связыванию lag-3 | |
| HRP20210561T1 (hr) | Mjesta za vezanje antitijela specifičnih za egfrviii | |
| JP7068825B2 (ja) | Ｃｄ３８に結合する抗体治療剤 | |
| HRP20220865T1 (hr) | T stanični receptori | |
| NZ750366A (en) | Chimeric antigen receptors targeting bcma and methods of use thereof | |
| HRP20201031T1 (hr) | Anti-ctla-4 protutijela i postupci njihove upotrebe | |
| HRP20230512T1 (hr) | Novi peptidi i kombinacija peptida za uporabu u imunoterapiji protiv karcinoma jajnika i drugih karcinoma | |
| HRP20180269T1 (hr) | Anti-cd40 protutijela, upotrebe i postupci | |
| HRP20221375T1 (hr) | Transfecirane t-stanice i t-stanični receptori za upotrebu u imunoterapiji protiv raka | |
| HRP20212023T1 (hr) | Modulokini temeljeni na il-15 i il-15ralpha sushi domeni | |
| HRP20230623T1 (hr) | Polipeptidi koji sadrže fc domenu s promijenjenom glikozilacijom i smanjenom efektorskom funkcijom | |
| JP2017533698A5 (hr) | ||
| NO346945B1 (no) | Anti-NKG2A-antistoffer og anvendelser derav | |
| CN111718415B (zh) | 一种抗tigit纳米抗体及其应用 | |
| HRP20231645T1 (hr) | T stanični receptori | |
| US10934361B2 (en) | Antibody therapeutics that bind CD123 | |
| US20160297882A1 (en) | Antibody Therapeutics That Bind CD123 | |
| CN112437776A (zh) | 间皮素和cd137结合分子 | |
| US20230144405A1 (en) | Human anti-cd33 antibodies and uses thereof |